Comparative Pharmacology
Head-to-head clinical analysis: METAPROTERENOL SULFATE versus SEREVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAPROTERENOL SULFATE versus SEREVENT.
METAPROTERENOL SULFATE vs SEREVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-2 adrenergic receptor agonist that activates adenylate cyclase, increasing intracellular cyclic AMP leading to bronchodilation and inhibition of mast cell mediator release.
Selective long-acting beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
2.5 mg (0.25 mL of 1% solution) by nebulization every 6-8 hours. For oral, 20 mg every 6-8 hours.
50 mcg (2 inhalations) twice daily via inhalation; maximum 100 mcg/day.
None Documented
None Documented
Terminal elimination half-life: 2-6 hours. Clinical context: Shorter half-life requires frequent dosing; prolongation in renal impairment.
Terminal elimination half-life of 5.5 hours (range 3–7 hours). No dose adjustment in renal or hepatic impairment; accumulation can occur in severe hepatic disease, monitor.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites.
Primarily hepatic metabolism via CYP3A4; ~60% excreted in feces as parent drug and metabolites; ~25% in urine as metabolites; negligible (0.5%) unchanged drug in urine.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist